Abstract
We report the use of a bispecific F(ab')2 antibody to target the ribosome-inactivating protein saporin to the surface antigen CD22 in the treatment of low-grade, end-stage, B-cell lymphoma. Four patients were treated. Toxic effects were minimal (grade I), with mild fever, weakness, and myalgia for 1-2 days after treatment. One patient showed an antibody response to mouse Fab' and saporin. All patients showed rapid and beneficial responses to treatment with improvements in most disease sites and in peripheral blood cytopenia. The responses were short-lived (less than 28 days) but further study of this targeting system is warranted.
References
May 16, 1992·Lancet·B FaliniG Pizzolo
Feb 6, 1988·Lancet·A G StansfeldO Mioduszewska
Nov 1, 1993·Nuclear Medicine and Biology·D S WilburR W Atcher
Jun 1, 1993·Immunology Today·E S VitettaJ W Uhr
Citations
Jun 14, 1995·Journal of Immunological Methods·A J GeorgeM J Glennie
Jul 1, 1996·Leukemia Research·R R FrenchM J Glennie
Jan 20, 1998·Journal of Immunological Methods·O ManzkeH Bohlen
Jun 6, 2000·Advanced Drug Delivery Reviews·L Zardi, D Neri
Jun 6, 2000·Advanced Drug Delivery Reviews· de Leij LB J Kroesen
Sep 12, 1998·British Journal of Haematology·S SforziniS Ferrini
Nov 10, 2011·Toxins·Letizia PolitoAndrea Bolognesi
Oct 10, 2013·Toxins·Letizia PolitoAndrea Bolognesi
Feb 5, 2003·Advanced Drug Delivery Reviews·Ying Cao, Laura Lam
Mar 1, 1996·Nature Medicine·L H PaiI Pastan
Sep 24, 2015·Applied Microbiology and Biotechnology·Ouafae AkkouhWai Yee Chan
Apr 15, 1999·Seminars in Cancer Biology·G T Stevenson, M S Cragg
Feb 14, 2018·Toxins·Francesco GiansantiRodolfo Ippoliti
Sep 14, 2019·Blood Advances·Chunyan GaoQizhen Shi
May 26, 2017·Biomedicines·Letizia PolitoMassimo Bortolotti